APA (7th ed.) Citation

Tang, X., Liu, B., Zhang, C., Tang, W., Liang, S., Xiao, Y., . . . Li, Z. (2021). SENP2 Reduces Hepatocellular Carcinoma Stemness and Improves Sorafenib Sensitivity Through Inactivating the AKT/GSK3β/CTNNB1 Pathway. Frontiers in Oncology, 11, . https://doi.org/10.3389/fonc.2021.773045

Chicago Style (17th ed.) Citation

Tang, Xiaohui, Bohao Liu, Chen Zhang, Wenbin Tang, Shitian Liang, Yadan Xiao, Ruoyu Deng, and Zhuan Li. "SENP2 Reduces Hepatocellular Carcinoma Stemness and Improves Sorafenib Sensitivity Through Inactivating the AKT/GSK3β/CTNNB1 Pathway." Frontiers in Oncology 11 (2021). https://doi.org/10.3389/fonc.2021.773045.

MLA (9th ed.) Citation

Tang, Xiaohui, et al. "SENP2 Reduces Hepatocellular Carcinoma Stemness and Improves Sorafenib Sensitivity Through Inactivating the AKT/GSK3β/CTNNB1 Pathway." Frontiers in Oncology, vol. 11, 2021, https://doi.org/10.3389/fonc.2021.773045.